Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add filters

Language
Document Type
Year range
1.
British Journal of Dermatology ; 186(6):e252-e253, 2022.
Article in English | EMBASE | ID: covidwho-1956698

ABSTRACT

Since the approval of vaccines for SARS-CoV-2, dermatologists have sought to characterize the adverse cutaneous effects associated with those vaccines. We describe two cases of pityriasis rubra pilaris (PRP) following vaccination against COVID-19. A 51-year-old man initially developed an erythematous scaly rash in his groin and over his knees 3 days following the first dose of the Pfizer COVID-19 vaccine. He presented after the second dose, as the rash worsened, affecting 60% body surface area (BSA). On examination there was an erythematous skin eruption extending from his scalp to both arms and the proximal thighs with sparing of the periumbilical area. There was no evidence of palmoplantar hyperkeratosis. The second case is a 51-year-old man presented with an itchy, erythematous rash affecting >80% BSA, 2 days after his first dose of the AstraZeneca COVID-19 vaccine. On examination there were multiple erythematous annular plaques, some of which were becoming more confluent, with islands of sparing. There was no evidence of palmoplantar hyperkeratosis. Differential diagnosis in both included drug-induced psoriasis and PRP. Histopathological diagnosis was consistent with PRP. Management of both cases included ruling out occult malignancy and infectious causes. Both patients were treated with acitretin and topical steroids. It is important to recognize this serious adverse event early so appropriate treatment can be initiated. When the culprit is the COVID-19 vaccine, typical features like palmoplantar hyperkeratosis may not be present. If PRP occurs after the first dose then discussion with the patient, weighing the risks and benefits including worsening of disease compared with the possibility of severe disease/death from COVID-19, is needed.

2.
Clin Exp Dermatol ; 47(1): 188-190, 2022 Jan.
Article in English | MEDLINE | ID: covidwho-1352459

ABSTRACT

We describe a case of a pityriasis rubra pilaris (PRP)-like eruption occurring following administration of the Pfizer-Biontech mRNA COVID-19 vaccine, with worsening of the condition following the second dose. To our knowledge, this is the first reported case of a PRP-like eruption as a cutaneous adverse event of the Pfizer-Biontech mRNA COVID-19 vaccine.


Subject(s)
BNT162 Vaccine/adverse effects , COVID-19/prevention & control , Drug Eruptions/etiology , Pityriasis Rubra Pilaris/chemically induced , Drug Eruptions/pathology , Humans , Male , Middle Aged , Pityriasis Rubra Pilaris/pathology , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL